Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647 ·Status: COMPLETED ·Phase: PHASE3

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767 ·Status: COMPLETED ·Phase: PHASE3

Stroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKA

NCT02657616 ·Status: COMPLETED

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

NCT03490994 ·Status: UNKNOWN ·Phase: PHASE4

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

NCT02864758 ·Status: COMPLETED

The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients

NCT02646267 ·Status: UNKNOWN ·Phase: PHASE4

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi

NCT03926780 ·Status: COMPLETED ·Phase: PHASE3

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

NCT02240667 ·Status: COMPLETED

Anticoagulation Preference by AF Patients Study

NCT02607371 ·Status: COMPLETED

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

NCT02866175 ·Status: COMPLETED ·Phase: PHASE3

Resolution of Thrombi in Left Atrial Appendage With Edoxaban

NCT03840291 ·Status: COMPLETED ·Phase: PHASE4

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

NCT01729871 ·Status: COMPLETED ·Phase: PHASE3

Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence

NCT00562289 ·Status: COMPLETED ·Phase: PHASE3

Patient Convenience Study

NCT02597920 ·Status: COMPLETED

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

NCT02043808 ·Status: COMPLETED

Patient Convenience Study- NIS RELATE

NCT02849509 ·Status: COMPLETED

Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)

NCT06402851 ·Status: RECRUITING ·Phase: PHASE4

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)

NCT02906527 ·Status: UNKNOWN

Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies

NCT02610153 ·Status: COMPLETED

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

NCT02769078 ·Status: COMPLETED

Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

NCT05825573 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

NCT02090543 ·Status: COMPLETED

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

NCT02066662 ·Status: COMPLETED ·Phase: PHASE4

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

NCT03189069 ·Status: COMPLETED

Patient Convenience Study (RE-SONANCE)

NCT02684981 ·Status: COMPLETED